<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864913</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00017454</org_study_id>
    <nct_id>NCT03864913</nct_id>
  </id_info>
  <brief_title>Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents</brief_title>
  <official_title>Investigating the Efficacy of Subcutaneous Testosterone Compared to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial studies the efficacy of subcutaneous (SQ) testosterone compared to intramuscular&#xD;
      (IM) testosterone therapy during the first 6 months of pubertal induction in transgender male&#xD;
      adolescents. Describes rate of adverse effects, masculinizing effects and quality of life&#xD;
      while receiving testosterone. Evaluates clinic utilization required for testosterone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. Determine the efficacy of SQ testosterone compared to IM testosterone therapy.&#xD;
           Hypothesis: SQ testosterone is equally efficacious to IM testosterone in achieving&#xD;
           mid-pubertal testosterone levels and masculinizing physical changes in transgender male&#xD;
           adolescents after 6 months.&#xD;
&#xD;
        2. Determine the rate of adverse reactions of SQ and IM testosterone during the first 6&#xD;
           months of treatment.&#xD;
&#xD;
           Hypothesis: SQ testosterone results in equal or fewer adverse reactions than IM&#xD;
           testosterone.&#xD;
&#xD;
        3. Evaluate quality of life (QOL) and satisfaction of injection technique for SQ and IM&#xD;
           testosterone.&#xD;
&#xD;
           Hypothesis: Subjects receiving SQ testosterone will report equal or superior quality of&#xD;
           life and satisfaction with injection technique compared to IM testosterone as SQ is less&#xD;
           painful and easier to administer at home.&#xD;
&#xD;
        4. Evaluate and compare the number of clinical visits required for testosterone injections&#xD;
           by transgender male patients receiving SQ and IM therapy.&#xD;
&#xD;
      Hypothesis: Subjects using SQ testosterone will have fewer clinic visits than those using IM&#xD;
      testosterone. This may impact healthcare-related costs.&#xD;
&#xD;
      Study Outline:&#xD;
&#xD;
      6 month study consisting of three study visits at baseline, 3 months and 6 months. Optional&#xD;
      cross over of injection modality from 6-9 months. At each visit subjects complete blood work&#xD;
      and questionnaires to determine testosterone peak and trough levels as well as biochemical&#xD;
      adverse effects, quality of life, masculinizing effects and medication experience.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized arm (SQ, IM), as well as non-randomized SQ and non-randomized IM.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum testosterone level</measure>
    <time_frame>Two lab draws, before and after testosterone injection, drawn at 3 month and 6 month follow up</time_frame>
    <description>Trough and peak serum testosterone level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse effects</measure>
    <time_frame>Assessed at 3 month and 6 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL questionnaire score</measure>
    <time_frame>Completed at baseline, 3 month and 6 month follow up</time_frame>
    <description>Validated pediatric quality of life tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Masculinizing effects</measure>
    <time_frame>Completed at 3 month and 6 month follow up</time_frame>
    <description>Self reported, questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication experience</measure>
    <time_frame>Completed at 3 month and 6 month follow up</time_frame>
    <description>Self reported, questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Health Services for Transgender Persons</condition>
  <condition>Transgender Persons</condition>
  <arm_group>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to either SQ or IM testosterone injections follow study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone injection</intervention_name>
    <description>SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PedsQL questionnarie</intervention_name>
    <description>Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Masculinizing effects questionnaire</intervention_name>
    <description>Subjects complete self-reported questionnaire at 3 month and 6 month study visits.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication experience questionnaire</intervention_name>
    <description>Subjects complete self-reported questionnaire at 3 month and 6 month study visits.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Testosterone naive&#xD;
&#xD;
          -  Transgender male&#xD;
&#xD;
          -  14-19 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transgender males who have received testosterone therapy in the past&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Transgender male</gender_description>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara Connelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kara Connelly</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gender affirming care</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

